The role of ethylenedimine tetraacetic acid (EDTA) as in vitro anticoagulant for diagnostic purposes

被引:184
作者
Banfi, Giuseppe
Salvagno, Gian Luca
Lippi, Giuseppe
机构
[1] Univ Milan, Sch Med, IRCCS Galeazzi, I-20161 Milan, Italy
[2] Univ Milan, Sch Med, Chair Clin Biochem, Milan, Italy
[3] Univ Verona, Dipartimento Sci Morfol Biomed, Sez Chim & Microscopia Clin, I-37100 Verona, Italy
关键词
anticoagulants; blood; laboratory testing; plasma; serum;
D O I
10.1515/CCLM.2007.110
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Anticoagulants are used to prevent clot formation both in vitro and in vivo. In the specific field of in vitro diagnostics, anticoagulants are commonly added to collection tubes either to maintain blood in the fluid state for hematological testing or to obtain suitable plasma for coagulation and clinical chemistry analyses. Unfortunately, no universal anticoagulant that could be used for evaluation of several laboratory parameters in a sample from a single test tube is available so far. Ethylenediamine tetraacetic acid (EDTA) is a polyprotic acid containing four carboxylic acid groups and two amine groups with lone-pair electrons that chelate calcium and several other metal ions. Calcium is necessary for a wide range of enzyme reactions of the coagulation cascade and its removal irreversibly prevents blood clotting within the collection tube. Historically, EDTA has been recommended as the anticoagulant of choice for hematological testing because it allows the best preservation of cellular components and morphology of blood cells. The remarkable expansion in laboratory test volume and complexity over recent decades has amplified the potential spectrum of applications for this anticoagulant, which can be used to stabilize blood for a variety of traditional and innovative tests. Specific data on the behavior of EDTA as an anticoagulant in hematology, including possible pitfalls, are presented. The use of EDTA for measuring cytokines, protein and peptides, and cardiac markers is described, with an outline of the protection of labile molecules provided by this anticoagulant. The use of EDTA in proteornics and in general clinical chemistry is also described in comparison with other anticoagulants and with serum samples. Finally, the possible uses of alternative anticoagulants instead of EDTA and the potential use of a universal anticoagulant are illustrated.
引用
收藏
页码:565 / 576
页数:12
相关论文
共 143 条
  • [1] INVITRO STABILITY OF HUMAN ATRIAL-NATRIURETIC-PEPTIDE (H-ANP)
    ARTNERDWORZAK, E
    LINDNER, H
    PUSCHENDORF, B
    [J]. CLINICA CHIMICA ACTA, 1991, 203 (2-3) : 235 - 242
  • [2] BANFI G, 1994, CLIN CHEM, V40, P833
  • [3] BANFI G, 1995, EUR J CLIN CHEM CLIN, V33, P99
  • [4] Banfi G, 2003, J SPORT MED PHYS FIT, V43, P223
  • [5] BANFI G, 1988, LAB MED, V22, P87
  • [6] BANFI G, 1987, BIOCH CLIN, V11, P957
  • [7] Influences of blood sample processing on low-molecular-weight proteome identified by surface-enhanced laser desorption/ionization mass spectrometry
    Banks, RE
    Stanley, AJ
    Cairns, DA
    Barrett, JH
    Clarke, P
    Thompson, D
    Selby, PJ
    [J]. CLINICAL CHEMISTRY, 2005, 51 (09) : 1637 - 1649
  • [8] Screening for EDTA-dependent deviations in platelet counts and abnormalities in platelet distribution histograms in pseudothrombocytopenia
    Bartels, PCM
    Schoorl, M
    Lombarts, AJPF
    [J]. SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 1997, 57 (07) : 629 - 636
  • [9] SERUM HEMAGGLUTINATING PROPERTY DEPENDENT UPON POLYCARBOXYL GROUPS
    BECK, ML
    FREIHAUT, B
    HENRY, R
    PIERCE, S
    BAYER, WL
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1975, 29 (01) : 149 - 156
  • [10] BEHESHTI I, 1994, CLIN CHEM, V40, P2088